Winter 2027 Symposium Agenda

Optimizing Antibody–Drug Conjugate Therapy Across Solid Tumors: Sequencing, Toxicity Management and Next Frontiers

Thursday, January 28, 2027 – Time: 8 am – 12:21 pm PT *(times subject to change)*
NRG Oncology 2027 Winter Meeting - Las Vegas, Nevada

Program Chairs: Kathleen Moore, MD / Co-Chair Paolo Tarantino, MD, PhD / Co-Chair Joyce Liu, MD

Program Description

The use of antibody-drug conjugate (ADC) therapy has ushered in a new era in oncology, significantly transforming the management of a range of solid tumor malignancies. This session explores the expanding role of ADCs in the treatment of ovarian, cervical, endometrial, breast, lung, genitourinary and gastrointestinal cancers, highlighting their impact on clinical practice and patient outcomes. Rather than a survey of individual agents, the disease-specific talks focus on the current landscape, practice-changing advances, and the open questions that remain in each field. The latest clinical trial results are reviewed alongside challenging clinical scenarios in patients treated with ADCs. Expert-led discussions provide evidence-based perspectives on drug selection, biomarkers, sequencing, toxicity management, and combination strategies. The program also reviews the future landscape of care and current and upcoming clinical trials, equipping attendees with knowledge that can be applied in oncology practice.

Interactive case vignettes offer practical guidance on patient selection, therapeutic strategies, sequencing across lines of therapy and drug classes, and the management of adverse effects associated with ADCs. A patient voice is included to address tolerability and quality of life as ADCs move into earlier lines and maintenance settings. Ongoing and planned pivotal clinical trials are discussed, along with the future of clinical trial design in the era of current ADCs and novel future therapies.

Learning Objectives

Following this activity, participants will be better able to:

1. **Explain** the development and mechanism of action of antibody-drug conjugates (ADCs) and **identify** mechanisms of resistance.
2. **Discuss** the clinical application of ADCs in the treatment of gynecologic, breast, lung, genitourinary (GU), and gastrointestinal (GI) malignancies.
3. **Develop** strategies for sequencing ADCs across lines of therapy and with other drug classes.
4. **Recognize and manage** adverse events associated with ADC therapy using a multidisciplinary approach.

Target Audience

This symposium is intended for a broad oncology-focused audience, including members and non-members. Participants may include physicians, research staff, early-career investigators, clinical research associates, basic scientists, medical physicists, clinical trial nurses, patient advocates, and other healthcare professionals involved in cancer treatment and research.

CME Credits

This symposium is estimated to earn 4.25 category 1 credits.

SYMPOSIUM AGENDA		
6:30 am – 8:00 am	**Breakfast Buffet**	
8:00 am	**Welcome/Opening Remarks**	**Kathleen Moore, MD**
8:05 – 9:50 am	**Session 1 - ADCs Today: The Evolving Landscape Across Solid Tumors**	**Moderator: Joyce Liu, MD**
8:05 – 8:20	**History and Pharmacology of ADCs: Evolving Understanding over 40 Years of Development**	**Paolo Tarantino, MD, PhD**
8:20 – 8:35	**Breast: Practice-changing Advances and Open Questions (e.g., DESTINY-Breast 11, ASCENT-03/04; distinct populations, biomarkers)**	**Heather McArthur, MD**
8:35 – 8:50	**Thoracic: Developing ADCs in a Biomarker-Rich Landscape of Small-Molecule Therapies**	**Julia Rotow, MD**
8:50 – 9:05	**GI: Current Landscape and Where the Field is Headed**	**Zev Wainberg, MD**
9:05 – 9:20	**GU: Current Landscape and Where the Field is Headed**	**Emanuele Crupi, MD**
9:20 – 9:35	**Gynecologic: Current Landscape and Where the Field is Headed**	**BJ Rimel, MD**
9:35 – 9:50 am	**Panel Discussion with Q/A**	**ALL**
9:50 – 10:05 am	**Coffee Break**	
10:05 – 11:20 am	**Session 2 - ADC Selection, Sequencing, and Toxicity Management**	**Moderator: Kathleen Moore, MD**
10:05 – 10:20	**ADCs: What the people with lived experience (you call us patients) are experiencing**	**Kelly Shanahan, MD**
10:20 – 10:35	**Biomarkers and next-generation target assessment: digital/multiplexed pathology and quantitative expression beyond 1+/2+/3+**	**Brook Howitt, MD**
10:35 – 10:50	**ADC Toxicity Management I: N/V, ocular effects, and GI/endocrine effects**	**Shannon Westin, MD**
10:50 – 11:05	**ADC Toxicity Management II: ILD/pulmonary and mucositis**	**Hope Rugo, MD***
11:05 – 11:20 am	**Panel Discussion with Q/A (incl. patient)**	**ALL**
11:20 – 12:21 pm	**Session 3 - Combinations and the Next Decade in ADC Development**	**Moderator: Paolo Tarantino, MD, PhD**
11:20 – 11:35	**ADC Combinations: ADC+IO and ADC+ADC (e.g., EV+SG in bladder)**	**Bradley McGregor, MD**
11:35 – 11:50	**ADC Combinations with PARP inhibitors (e.g., T-DXd + olaparib data)**	**Elizabeth Lee, MD**
11:50 – 12:05	**ADC Trial Design in 2027: challenges and opportunities**	**Dimitrios Zardavas, MD**
12:05 – 12:21 pm	**Panel Discussion with Q/A**	**ALL**
12:21 pm	**Closing Remarks**	**K. Moore, MD, J. Liu, MD and P. Tarantino, MD, PhD**